insights_auto
Why is FARN down ၃.၉၂%?
Dive Deeperchevron_right
FARN:LON
Faron Pharmaceuticals Oy
၃၅.၀၇ GBX
arrow_downward
-၃.၉၂%(-၁.၄၃) 1D
အောက် ၁၄, GMT+၁ ၁၆:၃၀:၀၀ · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
၃၆.၇၀ GBX
High
၃၈.၀၀ GBX
Low
၃၅.၀၇ GBX
Mkt. cap
၇.၁၂ ကုဋေ
Avg. vol.
၄.၁၂ သောင်း
Volume
၁.၀၄ သောင်း
52-wk high
၁၉၃.၅၈ GBX
52-wk low
၃၄.၀၀ GBX
EPS
-၀.၁၀ GBX
Shares outstanding
၃.၁၀ ကုဋေ
No. of employees
၃၆
Open
၃၆.၇၀ GBX
High
၃၈.၀၀ GBX
Low
၃၅.၀၇ GBX
Mkt. cap
၇.၁၂ ကုဋေ
Avg. vol.
၄.၁၂ သောင်း
Volume
၁.၀၄ သောင်း
52-wk high
၁၉၃.၅၈ GBX
52-wk low
၃၄.၀၀ GBX
EPS
-၀.၁၀ GBX
Shares outstanding
၃.၁၀ ကုဋေ
No. of employees
၃၆
News stories
From web sources and news partners
Stocktwits
·
ပြီးခဲ့သည့် ၁ နာရီ
S&P 500, Nasdaq See Worst Day In Over Two Months As Chipmaker Rout Deepens, CPI Data Comes In Hot — AAPL, SPCX, DRAM, SOXX In Focus
MarketBeat
·
ပြီးခဲ့သည့် ၂၅ မိနစ်
CoreWeave (NASDAQ:CRWV) CRO Jonathan Jones Sells 15,811 Shares of Stock
The Motley Fool
·
ပြီးခဲ့သည့် ၁၁ မိနစ်
The S&P 500 Has Risen 30.6% in the First 20 Months of Trump's Second Term, Just Ahead of the 28.5% Gain Over the Same Stretch of His First Term. Here's Why That Comparison Matters for Investors Heading Into the Midterms.
Bloomberg.com
·
ပြီးခဲ့သည့် ၅ နာရီ
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy